文献速递心力衰竭与心肌病

神经氨酸酶1是实验性心肌肥厚的驱动因子

Neuraminidase 1 is a driver of experimental cardiac hypertrophy.
PubMed 文献 · Eur Heart J · 2021-01-01

本研究在小鼠、大鼠肥厚心脏及肥厚型心肌病患者(n=7,对照n=7)中证实神经氨酸酶1(NEU1)高表达,主要定位于心肌细胞。心肌细胞特异性NEU1缺失减轻压力负荷或异丙肾上腺素诱导的肥厚,过表达则加重;机制上NEU1入核与GATA4互作促进Nppa、Nppb表达。筛选出的化合物C-09与人NEU1结合(KD=0.38 μM)并可预防心脏重构,扎那米韦和奥司他韦亦抑制哺乳动物NEU1并显示心脏保护新用途。

要点

  • NEU1在实验性及人肥厚型心肌病心脏中高表达,主要位于心肌细胞
  • 心肌细胞NEU1缺失减轻、过表达加重病理性心肌肥厚
  • C-09及抗流感药扎那米韦、奥司他韦抑制NEU1并显示心脏保护作用

核心结论

  • NEU1是心肌肥厚的关键驱动因子,抑制NEU1为心血管疾病治疗开辟全新领域。

研究设计与样本

  • 实验性基础研究,结合小鼠和大鼠肥厚模型、肥厚型心肌病患者(n=7)与健康对照(n=7)的心脏组织分析。

主要发现

  • NEU1在鼠及人肥厚心脏中高表达,与心肌肌钙蛋白T共定位提示主要位于心肌细胞。
  • 心肌细胞特异性NEU1缺失减轻横主动脉缩窄或盐酸异丙肾上腺素输注诱导的肥厚表型,NEU1过表达加重心肌肥厚。
  • NEU1转位入核与GATA4互作,促进胎儿基因Nppa和Nppb表达。
  • 化合物C-09与人NEU1结合KD=0.38 μM,在细胞和动物模型中有效预防心脏重构。
  • 扎那米韦和奥司他韦有效抑制哺乳动物NEU1,显示心脏保护的新适应证。

关键数值与推荐

  • 人NEU1结合亲和力KD=0.38 μM(化合物C-09);患者与对照各n=7。

临床怎么用

  • 提示NEU1可作为心肌肥厚干预的新靶点,C-09及抗流感药物扎那米韦、奥司他韦具转化潜力,尚需临床验证。

局限性

  • 机制与药物验证主要来自细胞和动物模型,人体数据仅为小样本表达验证(n=7对n=7)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Despite considerable therapeutic advances, there is still a dearth of evidence on the molecular determinants of cardiac hypertrophy that culminate in heart failure. Neuraminidases are a family of enzymes that catalyze the cleavage of terminal sialic acids from glycoproteins or glycolipids. This study sought to characterize the role of neuraminidases in pathological cardiac hypertrophy and identify pharmacological inhibitors targeting mammalian neuraminidases. METHODS AND RESULTS: Neuraminidase 1 (NEU1) was highly expressed in hypertrophic hearts of mice and rats, and this elevation was confirmed in patients with hypertrophic cardiomyopathy (n = 7) compared with healthy controls (n = 7). The increased NEU1 was mainly localized in cardiomyocytes by co-localization with cardiac troponin T. Cardiomyocyte-specific NEU1 deficiency alleviated hypertrophic phenotypes in response to transverse aortic constriction or isoproterenol hydrochloride infusion, while NEU1 overexpression exacerbated the development of cardiac hypertrophy. Mechanistically, co-immunoprecipitation coupled with mass spectrometry, chromatin immunoprecipitation, and luciferase assays demonstrated that NEU1 translocated into the nucleus and interacted with GATA4, leading to Foetal gene (Nppa and Nppb) expression. Virtual screening and experimental validation identified a novel compound C-09 from millions of compounds that showed favourable binding affinity to human NEU1 (KD = 0.38 μM) and effectively prevented the development of cardiac remodelling in cellular and animal models. Interestingly, anti-influenza drugs zanamivir and oseltamivir effectively inhibited mammalian NEU1 and showed new indications of cardio-protection. CONCLUSIONS: This work identifies NEU1 as a critical driver of cardiac hypertrophy and inhibition of NEU1 opens up an entirely new field of treatment for cardiovascular diseases.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Chen QQ, Ma G, Liu JF, et al. Neuraminidase 1 is a driver of experimental cardiac hypertrophy. Eur Heart J. 2021. PMID: 34179969. doi:10.1093/eurheartj/ehab347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。